Rare disease agency Cambridge Bio goes global in $35M buyout by Beth Snyder Bulik Wednesday, July 26, 2017 Specialists at rare disease drug launches, Cambridge BioMarketing was snapped up by an expansion-minded healthcare services firm, Ireland's UDG.
